Evaluation on Anti SARS COV 2 Antibody Titre and Human Genomic Characterization of Non Responder in the Vaccinated Candidates

Abstract

SARS-CoV-2 stands out as one of the infectious diseases that has newlineexhibited remarkable speed in its spread throughout human history, having emerged newlinein China and disseminated globally within approximately three to four months. In newlineDecember 2019, the quotWuhan Virusquot was initially identified in Wuhan, China, after a notable outbreak of pneumonia. The World Health Organisation (WHO) renamed the virus as SARS-CoV-2 due to its near genomic resemblance to the coronavirus illness previously known as COVID-19 on February 11, 2020. As of the WHO report on August 30, 2023, approximately 3,446 new cases of COVID-19 were documented, newlineand about 6.9 million fatalities were documented worldwide. The WHO states that newline5.1 million people received a complete vaccination and that approximately 5.5 million people received at least a single vaccine dosage. As of August 30, 2023, 44.9 million COVID-19 cases had been confirmed. Over 952 million people received a full dosage of the COVID-19 immunization, and 1.02 billion people received at least newlinea single vaccine dosage in India. Among SARS-CoV-2 infected individuals, newlineantibodies showed immune reactions focused on the genetic and structural elements present in the heavy-chain V-genes of multiple antibody classes. Studies on SARSCoV- newline2 antibodies revealed common specific IGHV genes in S-specific neutralizing newlineantibodies. One of the most often used IGHV genes for the production of antibodies is, remarkably, IGHV1-69. However, due to the substantial allelic variability, IGHV1-69-related antibody responses might show significant individual variances newline